Drug Trial Radar · NCT07142252
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
May 25, 2028
Study completion May 25, 2028
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.
Conditions
- Type 1 Diabetes Mellitus
Interventions
RezpegaldesleukinDrug
Rezpegaldesleukin will be dosed at 12 μg/kg for subcutaneous injection. Rezpegaldesleukin will be provided as a 1.5 mg/mL sterile solution in a vial for injection preparation. Study agent injections will be administered in the abdomen, back of the upper arm or the upper thigh of the participant.
PlaceboDrug
Sterile saline for injection. Placebo will be administered in the same volume and as the active comparator to maintain treatment masking.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The area under the stimulated C-peptide curve (AUC) Y_MAUC.Time frame: 12 Months
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California · Recruiting
Barbara Davis Center for Diabetes
Aurora, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
USF Diabetes Center
Tampa, Florida · Recruiting
Indiana University-Riley Hospital for Children
Indianapolis, Indiana · Recruiting
Joslin Diabetes Center
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Columbia University
New York, New York · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt University
Nashville, Tennessee · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Benaroya Research Institute
Seattle, Washington · Recruiting
University of British Columbia
Vancouver, British Columbia, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.